Shuttle Pharma corporate update: Phase 2 glioblastoma trial 40% enrolled; no financial results

Shuttle Pharmaceuticals Holdings, Inc.

Phase 2 trial of Ropidoxuridine for glioblastoma: 17 of 40 initial patients enrolled (40%), 8 completed all 7 cycles.
Trial conducted at Georgetown, Allegheny Health Network, UNC, UVA, Hackensack, Miami Cancer Institute.
Diagnostics subsidiary entered sponsored research agreement with UCSF to develop PSMA ligand as theranostic.
CEO Dr. Anatoly Dritschilo invested $237,500 along with other investors in recent financing.
Launched new corporate website highlighting dual approach to cancer therapeutics and diagnostics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.